Table 11.9Fetal DNA

Author, year, country, EL, study designNo. of women analysed, inclusion/exclusion criteria, age, gestational age at testReference standard used, incidence of PEIndex test cut-offResultsComments and conclusion
Cotter (2004)859
Ireland, EL II, case–control study (nested and matched)
264 (88 cases and 176 controls)
IN: normotensive non- proteinuric women, male fetuses
EX: aneuploid fetuses 26.1 ± 5.9 years, 15.7 ± 3.6 weeks
BP ≥ 140/90 mmHg; Prot. ≥ 0.3 g/24 hours or 1+/2+ dipstick, Incidence n.r.fDNA Real-time PCR TaqMan SRY< 10 000 copies/ml< 50 000 >50 000SRY copies/ml
< 10 000: ST 94.32%, SP 32.39%, LR+ 1.39
< 50 000: ST 81.82%, SP 64.77%, LR+ 2.32
>50 000: ST 38.64%, SP 90.34%, LR+ 4.00
Increased fetal DNA is present in the maternal circulation in early pregnancy in women who subsequently develop pre-eclampsia and there appears to be a graded response between the quantity of fetal DNA and the risk of developing pre-eclampsia.
Leung (2001)860
Hong Kong, EL II, case–control study (nested and matched)
51 (18 cases and 33 controls), IN: singleton pregnancies, male fetuses
Age n.r.
11–22 weeks
DBP ≥ 90 mmHg 2x ≥ 4 hours apart or DBP ≥ 110 mmHg; Prot. ≥ 0.3 g/24 hours or 2+ dipstick 2x ≥ 4 hours apart, Incidence n.r.fDNA Real-time PCR TaqMan SRY ≥ 33.5 Geq/mlSRY
≥ 33.5 Geq/ml: ST 67%, SP 82%
(can’t calculate LRs)
Maternal plasma fetal DNA might be used as a marker for predicting pre-eclampsia.

From: 11, Screening for clinical problems

Cover of Antenatal Care
Antenatal Care: Routine Care for the Healthy Pregnant Woman.
NICE Clinical Guidelines, No. 62.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2008 Mar.
Copyright © 2008, National Collaborating Centre for Women’s and Children’s Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [www.cla.co.uk]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.